Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 21;5(8):e341.
doi: 10.1038/bcj.2015.48.

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

L Vincent  1   2   3 , P Ceballos  1 , C Plassot  2   3 , J C Méniane  1 , P Quittet  1 , R Navarro  1 , C Cyteval  4 , V Szablewski  5 , Z Y Lu  6 , T Kanouni  1 , J Moreaux  7   8 , G Cartron  1   2   3 , B Klein  2   3   7   8 , N Fegueux  1
Affiliations

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

L Vincent et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

References

    1. Perez-Simon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20:542–545. - PubMed
    1. Minnema MC, van de Donk NW, Zweegman S, Hegenbart U, Schonland S, Raymakers R, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008;41:779–784. - PubMed
    1. Zeiser R, Deschler B, Bertz H, Finke J, Engelhardt M. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant. 2004;34:1057–1065. - PubMed
    1. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.) Br J Haematol. 2014;164:811–821. - PMC - PubMed
    1. Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematology/oncology clinics of North America 2007211007–1034.vii-viii. - PubMed